Insider · CIK 0001749623

McKenna Mark C.

Reports to the SEC for 9 companies · PALO ALTO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001749623

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-03	APGEApogee Therapeutics, Inc.D Disposition to Issuer	Director	DDisposition to Issuer	−20K sh	—	—	0
2026-09-03	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−150K sh	—	—	0
2026-09-03	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−10.4K sh	—	—	0
2026-09-03	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−14.5K sh	—	—	0
2026-09-03	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−7,657 sh	—	—	0
2026-07-20	FRNMFreenome, Inc.C Conversion	Former Director	CConversion	+30K sh	—	—	30,000
2026-07-20	FRNMFreenome, Inc. · Class B Ordinary SharesC Conversion	Former Director	CConversion	−30K sh	—	—	0
2026-06-09	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+7,657 sh	—	—	7,657
2026-05-27	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+8,026 sh	—	—	8,026
2026-01-07	NAMSNewAmsterdam Pharma Co N.V.A Award	Director	AAward	+3,400 sh	—	—	10,360
2026-01-07	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director	AAward	+15.3K sh	—	—	15,300
2025-08-11	BBOTBridgeBio Oncology Therapeutics, Inc.M Exercise/Conversion	Former Director	MExercise/Conversion	+30K sh	—	—	30,000
2025-08-11	BBOTBridgeBio Oncology Therapeutics, Inc. · Class B ordinary sharesM Exercise/Conversion	Former Director	MExercise/Conversion	−30K sh	—	—	0
2025-06-17	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+14.5K sh	—	—	14,461
2025-05-29	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+25K sh	—	—	25,000
2025-01-07	NAMSNewAmsterdam Pharma Co N.V.A Award	Director	AAward	+6,960 sh	—	—	6,960
2025-01-06	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director	AAward	+32.5K sh	—	—	32,500
2024-12-12	APGEApogee Therapeutics, Inc.P Purchase	Director	PPurchase	+7,500 sh	$49.02	+$368K	7,500
2024-12-12	APGEApogee Therapeutics, Inc.P Purchase	Director	PPurchase	+12.5K sh	$49.85	+$623K	20,000
2024-07-17	NAMSNewAmsterdam Pharma Co N.V. · Option (right to buy)A Award	Director	AAward	+72.5K sh	—	—	72,500
2024-06-05	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+10.4K sh	—	—	10,370
2024-02-01	SYRESpyre Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2023-08-17	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+50K sh	—	—	50,000
2023-08-17	APGEApogee Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+100K sh	—	—	150,000
2023-06-16	Prometheus Biosciences, Inc.D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−178K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−161K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−133K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−20K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−482K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−566K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−290K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−247K sh	—	—	0
2023-06-16	Prometheus Biosciences, Inc.Stock Option (right to buy)D Disposition to Issuer	Director, Chairman, President and CEO	DDisposition to Issuer	−129K sh	—	—	0
2023-06-02	Prometheus Biosciences, Inc.M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	+123K sh	$2.90	+$355K	177,672
2023-06-02	Prometheus Biosciences, Inc.M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	+3 sh	$1.70	+$5.1	178,036
2023-06-02	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	−123K sh	—	—	161,105
2023-06-02	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	−3 sh	—	—	132,741
2023-03-15	Prometheus Biosciences, Inc.M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	+25K sh	$2.90	+$72.5K	80,144
2023-03-15	Prometheus Biosciences, Inc.S Sale	Director, Chairman, President and CEO	SSale	−25K sh	$116.14	−$2.9M	55,144
2023-03-15	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	−25K sh	—	—	283,633
2023-03-03	Prometheus Biosciences, Inc.M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	+10.6K sh	$3.70	+$39.3K	65,764
2023-03-03	Prometheus Biosciences, Inc.S Sale	Director, Chairman, President and CEO	SSale	−10.6K sh	$125.13	−$1.33M	55,144
2023-03-03	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	−10.6K sh	—	—	481,725
2023-03-01	Prometheus Biosciences, Inc.M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	+700 sh	$3.70	+$2,590	55,844
2023-03-01	Prometheus Biosciences, Inc.S Sale	Director, Chairman, President and CEO	SSale	−700 sh	$125.26	−$87.7K	55,144
2023-03-01	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	−700 sh	—	—	492,345
2023-02-17	Prometheus Biosciences, Inc.M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	+13.7K sh	$3.70	+$50.6K	68,824
2023-02-17	Prometheus Biosciences, Inc.S Sale	Director, Chairman, President and CEO	SSale	−13.7K sh	$125.10	−$1.71M	55,144
2023-02-17	Prometheus Biosciences, Inc.Stock Option (Right to Buy)M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	−13.7K sh	—	—	493,045
2023-02-16	Prometheus Biosciences, Inc.M Exercise/Conversion	Director, Chairman, President and CEO	MExercise/Conversion	+25K sh	$3.70	+$92.5K	80,144

Recent filings

Accepted (ET)
Sep 34
McKenna Mark C.0001140361-26-035615
SEC(opens sec.gov)
Jul 224
McKenna Mark C.0001749623-26-000003
SEC(opens sec.gov)
Jun 114
McKenna Mark C.0001104659-26-073060
SEC(opens sec.gov)
May 294
McKenna Mark C.0001636282-26-000065
SEC(opens sec.gov)
Jan 94
McKenna Mark C.0001193125-26-009269
SEC(opens sec.gov)
Aug 114
McKenna Mark C.0001213900-25-074368
SEC(opens sec.gov)
Jun 204
McKenna Mark C.0001104659-25-061276
SEC(opens sec.gov)
Jun 24
McKenna Mark C.0001636282-25-000066
SEC(opens sec.gov)
Jan 84
McKenna Mark C.0000950170-25-003566
SEC(opens sec.gov)
Dec 164
McKenna Mark C.0001104659-24-128588
SEC(opens sec.gov)
Jul 194
McKenna Mark C.0000950170-24-084945
SEC(opens sec.gov)

Companies

Address

C/O TCGX ACQUISITION CORP. II 245 LYTTON AVE., SUITE 350

PALO ALTO, CA, 94301